Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOMAX vs HYTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Off-label: adjunctive therapy for ureteral calculi expulsion
Benign prostatic hyperplasia (BPH),Hypertension (as monotherapy or in combination with other antihypertensives)
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Extensively metabolized in the liver via CYP3A4 and CYP2D6 enzymes.
Extensively metabolized in the liver via demethylation and dehydrogenation; multiple metabolites are formed, some pharmacologically active. CYP450 enzymes involved include CYP3A4 and CYP2D6.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
94-99% bound primarily to alpha-1 acid glycoprotein, with high affinity.
90–94% bound to albumin; free fraction 6–10%.
Approximately 16 L/kg (or 16 L for an average 70 kg patient), indicating extensive tissue distribution.
Vd: 3.9 L/kg (range 3.5–4.3 L/kg); large Vd indicates extensive tissue distribution, high affinity for vascular smooth muscle.
Oral bioavailability is approximately 90% (capsule) due to extensive absorption, with minimal first-pass metabolism.
Oral bioavailability: >90% (first-pass metabolism minimal); food does not affect absorption.
No adjustment required for GFR ≥10 m L/min; insufficient data for GFR <10 m L/min, use with caution.
No specific GFR-based dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; consider starting at 0.4 mg once daily. Child-Pugh Class C: Contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate (Child-Pugh A or B), initial dose 1 mg at bedtime, titrate cautiously; monitor for hypotension.
Not approved for pediatric use; safety and efficacy not established.
Not approved for use in children; safety and efficacy not established.
Same dosing as adults; monitor for orthostatic hypotension and dizziness. Consider starting at 0.4 mg once daily.
Initiate at 1 mg at bedtime to minimize orthostatic hypotension; titrate slowly. Elderly patients may experience increased sensitivity to hypotensive effects. Monitor blood pressure and renal function.
None.
None.
Orthostatic hypotension and syncope, especially upon initiation or dose increase,Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Hepatic impairment,Consideration of prostate cancer before initiating therapy
Orthostatic hypotension and syncope, especially with first dose (first-dose effect); dose titration recommended.,Priapism (rare); advise patient to seek immediate medical attention if erection persists >4 hours.,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on alpha-1 blockers.,Use with caution in patients with renal impairment or hepatic impairment.,May cause dizziness, drowsiness, or blurred vision; caution when driving or operating machinery.
Hypersensitivity to tamsulosin hydrochloride or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients with moderate to severe hepatic impairment
Hypersensitivity to terazosin or any component of the formulation.,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) may increase risk of hypotension (relative contraindication; use with caution).
Grapefruit juice may increase tamsulosin levels; avoid concurrent intake. High-fat meals can decrease absorption; administer 30 minutes after the same meal daily.
No significant food interactions. Avoid grapefruit juice as it may increase drug levels. Take with or without food. Limit alcohol intake as it may enhance orthostatic effects.
Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 30 times the human exposure). There are no adequate and well-controlled studies in pregnant women; use only if clearly needed. First trimester: no known increased risk of major malformations. Second/third trimester: no known specific fetal risks; however, alpha-blockers may cause hypotension in the mother, potentially affecting placental perfusion. No reports of teratogenic effects in humans.
Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at doses up to 200 mg/kg/day (rat) and 75 mg/kg/day (rabbit), but delayed fetal ossification was observed. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Tamsulosin is excreted in rat milk at concentrations 20-fold higher than maternal plasma. No human data exist; M/P ratio is not established. Due to potential for adverse effects (e.g., hypotension) in the nursing infant, breastfeeding is generally not recommended. Discontinue drug or bottle-feed, considering importance of therapy to mother.
It is not known whether terazosin is excreted in human milk. The M/P ratio is unknown. Caution is advised when administered to a nursing woman; consider developmental and health benefits of breastfeeding along with mother's clinical need.
No specific pharmacokinetic studies during pregnancy. Dose adjustments are not routinely recommended; however, hypotension risk may be increased due to pregnancy-related hemodynamic changes. Use the lowest effective dose and monitor for maternal hypotension to avoid fetal compromise.
No specific pharmacokinetic data in pregnancy. However, pregnancy may alter volume of distribution and hepatic clearance, potentially affecting drug levels. Dose adjustments may be needed based on clinical response and blood pressure monitoring. Start with lowest effective dose and titrate cautiously.
First-dose orthostatic hypotension is common; administer at bedtime. Avoid use in patients with history of cataract surgery due to intraoperative floppy iris syndrome (IFIS). Tamsulosin is not recommended for hypertension. Renal impairment does not require dose adjustment. Use caution with strong CYP3A4 inhibitors (e.g., ketoconazole) and PDE5 inhibitors (e.g., sildenafil) due to enhanced hypotensive effects.
HYTRIN (terazosin) is an alpha-1 adrenergic blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly to avoid orthostatic hypotension. Monitor blood pressure 2-3 hours after initial dose and after dose increases. May cause intraoperative floppy iris syndrome (IFIS) in cataract surgery; notify ophthalmologist. Use with caution in patients with renal impairment. Can be used alone or with other antihypertensives.
Take this medication approximately 30 minutes after the same meal each day to maintain consistent absorption.,Avoid getting up too quickly from a sitting or lying position to minimize dizziness.,Inform your ophthalmologist about tamsulosin use before any cataract surgery due to risk of floppy iris syndrome.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you miss a dose, skip it and take the next dose at the usual time; do not double the dose.
Take the first dose at bedtime to minimize dizziness or fainting.,Avoid sudden standing or sitting up quickly to prevent orthostatic hypotension.,Report any prolonged erections lasting more than 4 hours immediately.,Avoid driving or hazardous activities until you know how the drug affects you.,Do not stop taking abruptly; consult doctor for gradual dose reduction.,Inform all healthcare providers, especially eye surgeons, that you are taking terazosin.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOMAX vs HYTRIN, answered by our medical review team.
FLOMAX is a Alpha-1 Blocker that works by Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.. HYTRIN is a Alpha-1 Blocker that works by Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOMAX and HYTRIN depend on the specific clinical indication. These are both Alpha-1 Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOMAX is: 0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.. The standard adult dose of HYTRIN is: Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOMAX and HYTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOMAX is classified as Category C. Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 3. HYTRIN is classified as Category C. Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at do. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.